1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Generics

US FDA’s Drug Shortage Program On ‘Site Engagement’ To Be Nixed In GDUFA III

 
• By Derrick Gingery

Generics industry and FDA also debated inspection policies in lieu of travel and safety restrictions mandated by the pandemic.

Pharmaceutical manufacturing line
Facility inspections remained a discussion topic during GDUFA III negotiations in April. • Source: Alamy

A voluntary US Food and Drug Administration program intended to help manufacturers prevent product shortages will not survive the upcoming generic drug user fee reauthorization.

FDA and industry representatives agreed during a 22 April GDUFA III negotiating session “to not move forward with the Site...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Biosimilars & Generics